Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Prentiss Smith & Co. Inc.

Prentiss Smith & Co. Inc. decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 32.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,656 shares of the biopharmaceutical company’s stock after selling 1,779 shares during the period. Regeneron Pharmaceuticals makes up 2.4% of Prentiss Smith & Co. Inc.’s portfolio, making the stock its 19th biggest position. Prentiss Smith & Co. Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,211,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of REGN. Eudaimonia Advisors LLC raised its position in Regeneron Pharmaceuticals by 1.2% during the fourth quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock valued at $803,000 after acquiring an additional 11 shares in the last quarter. Drive Wealth Management LLC raised its position in Regeneron Pharmaceuticals by 4.0% during the fourth quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock valued at $273,000 after acquiring an additional 12 shares in the last quarter. MCF Advisors LLC raised its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 12 shares in the last quarter. Sutton Wealth Advisors Inc. raised its position in Regeneron Pharmaceuticals by 38.2% during the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 13 shares in the last quarter. Finally, Clearview Wealth Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 1.5% in the fourth quarter. Clearview Wealth Advisors LLC now owns 855 shares of the biopharmaceutical company’s stock valued at $751,000 after purchasing an additional 13 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $954.22, for a total value of $95,422.00. Following the sale, the director now owns 18,382 shares of the company’s stock, valued at approximately $17,540,472.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,022 shares of company stock valued at $10,552,991. 8.83% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $15.86 on Thursday, hitting $890.68. The company’s stock had a trading volume of 574,971 shares, compared to its average volume of 490,896. The firm has a market cap of $97.76 billion, a P/E ratio of 26.09, a price-to-earnings-growth ratio of 2.61 and a beta of 0.11. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The company has a fifty day moving average price of $950.58 and a 200-day moving average price of $893.29. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same quarter in the previous year, the firm posted $10.96 EPS. The business’s revenue for the quarter was up .6% on a year-over-year basis. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on REGN. Cantor Fitzgerald restated a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, April 15th. Royal Bank of Canada restated an “outperform” rating and issued a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. Morgan Stanley boosted their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 20th. Finally, Bank of America boosted their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday, April 12th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $977.77.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.